Remember, your tox data is bilingual. Make sure you are, too. Go break some eggs.
Your Weekly Briefing:
👀 Insights
How to Translate Your Nonclinical Strategy Into Investor Logic
Your nonclinical package isn't being read the way you wrote it. Investors aren't reading for science — they're reading for risk. Here are the five places nonclinical scientists routinely lose investors, and how to translate each one into the question they're actually asking.
💭 Myths v. Realities
Myth: If your nonclinical data is technically airtight, the investor conversation will go fine.
Reality: Investors aren't reading for science. They're reading for risk — and your tox data only lands if it's framed in their language. Same NOAEL, same species selection, same margin — completely different impact depending on whether you presented it as a regulatory artifact or a risk model.
🔧 Tools
Defender, Translator, or Strategist — find out in 10 questions.
Take the Quiz:
What kind of nonclinical storyteller are you?
A 10-question companion to this week's piece. Find out how investors actually read your nonclinical pitch — whether you're walking in as a Defender, a Translator, or a Strategist. Score yourself across the three, see where you're strong, and find the shift that moves you forward. Two minutes, one archetype, the playbook for what to do next.
⌛ Summer School Ends Tomorrow!
Don’t miss your chance to have nonclinical down to a science (pun intended). Promo ends tomorrow and there’s only ✌️ 1:1 spots left! Use code SUMMERSCHOOL.
